Skip to main content
Premium Trial:

Request an Annual Quote

J&J Seeks Authorization

Johnson & Johnson is seeking an Emergency Use Authorization for its SARS-CoV-2 vaccine from the US Food and Drug Administration, CNN reports.

J&J announced last week that its adenovirus-vector SARS-CoV-2 vaccine — which is offered in a one-dose regimen — has a 66 percent efficacy rate in preventing moderate-to-severe COVID-19. The company's findings, though, indicated that the candidate vaccine may be less effective against the viral strain identified in South Africa.

CNN notes that the FDA has scheduled a meeting for later this month of its Vaccines and Related Biological Products Advisory Committee, which will examine the company's vaccine data and make a recommendation. If the FDA is to issue an EUA for J&J's vaccine, it would not then come until the end of the month, CNN adds.

"Adding a third vaccine to the mix would add both supply and flexibility to the struggling US efforts to vaccinate the population," CNN says, adding that J&J's vaccine, in addition to being given as a single dose, and can be stored for months at refrigerator temperatures.

The FDA has previously authorized SARS-CoV-2 vaccines from Pfizer-BioNTech and Moderna.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.